Search
Scientists are learning that — in a literal sense — metastasis is wound healing gone wrong.
Results from studies in cell cultures and mouse models suggest that the experimental targeted therapy PU-H71 may be effective against one of the most aggressive forms of breast cancer.
Originally explored as a cancer drug, the tree-derived chemical is now being mined for its antiviral properties.
Memorial Sloan Kettering scientists have engineered a tiny particle that could ferry drugs directly to the kidneys and prevent their uptake in other organs.
By looking at how DNA is packaged in cells, scientists are teasing apart a long-standing conundrum about the immune response to cancer.
Cell biologist Philipp Niethammer discusses what the zebrafish can teach us about how the body heals.
Memorial Sloan Kettering Cancer Center is one of six leading institutions that will share in a $120 million gift from a foundation created by American billionaire Daniel K. Ludwig.
Therapies that target genetic alterations in tumors are showing promise for many cancer patients, but challenges in developing these new treatments remain.
Memorial Sloan Kettering researchers are studying how drugs that reverse malfunctioning proteins may treat disease.
As an autoimmune disease, Type 1 diabetes raises important questions about immune cell activity that have broad implications for immunotherapy.